Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

References

• SEER Cancer Statistics Factsheets: Female Breast CancerNational Cancer InstituteBethesda, MD Available from: http://seer.cancer.gov/statfacts/html/breast.htmlAccessed May 13, 2016
   Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines^®)Breast Cancer Version 22016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed May 13, 2016
   Google Scholar
• SpitaleAMazzolaPSoldiniDMazzucchelliLBordoniABreast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of SwitzerlandAnn Oncol200920462863519074747
   PubMed Web of Science ®Google Scholar
• LundMJButlerENHairBYAge/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first reportCancer2010116112549255920336785
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFAgliettaMTrastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnn Oncol200718697798417229773
   PubMed Web of Science ®Google Scholar
• HeinemannVDi GioiaDVehling-KaiserUA prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancerAnn Oncol201122360360820724574
   PubMed Web of Science ®Google Scholar
• RedanaSDonadioMNolèFTrastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparisonBMC Cancer2010102820122160
   PubMed Web of Science ®Google Scholar
• IshidaTKibaTTakedaMPhase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanesCancer Chemother Pharmacol200964236136919082596
   PubMed Web of Science ®Google Scholar
• SatoNSanoMTabeiTCombination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II studyBreast Cancer200613216617116755112
   PubMedGoogle Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• KümlerITuxenMKNielsenDLA systematic review of dual targeting in HER2-positive breast cancerCancer Treat Rev201440225927024080156
   PubMed Web of Science ®Google Scholar
• ChungACuiXAudehWGiulianoACurrent status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceClin Breast Cancer201313422323223829888
   PubMed Web of Science ®Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther2005471086109516020666
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLLittlefieldBAJordanMAInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther2008772003201118645010
   PubMed Web of Science ®Google Scholar
• SmithJAWilsonLAzarenkoOZhuXLewisBMLittlefieldBAJordanMAEribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityBiochemistry20104961331133720030375
   PubMed Web of Science ®Google Scholar
• JordanMAKamathKHow do microtubule-targeted drugs work? An overviewCurr Cancer Drug Targets20077873074218220533
   PubMed Web of Science ®Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol200927182954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol201028253922392820679609
   PubMed Web of Science ®Google Scholar
• AogiKIwataHMasudaNA phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancerAnn Oncol20122361441144821989327
   PubMed Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet2011377976991492321376385
   PubMed Web of Science ®Google Scholar
• Halaven (eribulin mesylate) injection [prescribing information]Woodcliff Lake, NJEisai Inc.2016
   Google Scholar
• WilksSPuhallaSO’ShaughnessyJPhase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancerClin Breast Cancer201414640541225024001
   PubMed Web of Science ®Google Scholar
• Mohd SharialMSCrownJHennessyBTOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancerAnn Oncol201223123007301622865781
   PubMed Web of Science ®Google Scholar
• OlsonEMullinsDWhen standard therapy fails in breast cancer: current and future options for HER2-positive diseaseJ Clin Trials20133100012924527366
   PubMedGoogle Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• SauraCGarcia-SaenzJAXuBSafety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201432323626363325287822
   PubMed Web of Science ®Google Scholar
• ZhaoMPanXLaymanRA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancerInvest New Drugs20143261285129424894652
   PubMed Web of Science ®Google Scholar
• BachelotTGarcia-SaenzJAVermaSSunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyBMC Cancer20141416624606768
   PubMed Web of Science ®Google Scholar
• von MinckwitzGdu BoisASchmidtMTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 studyJ Clin Oncol200927121999200619289619
   PubMed Web of Science ®Google Scholar
• Von MinckwitzGZielinskiCMaarteenseECapecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) [abstract]J Clin Oncol20082615S102518309937
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCAltorjaiGCapecitabine and trastuzumab in heavily pretreated metastatic breast cancerJ Clin Oncol200725253853385817679724
   PubMed Web of Science ®Google Scholar
• HurvitzSADirixLKocsisJPhase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol20133191157116323382472
   PubMed Web of Science ®Google Scholar
• ServitjaSRamosMGilMMulticenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2Anticancer Drugs201223223924622112931
   PubMed Web of Science ®Google Scholar
• AnderssonMLidbrinkEBjerreKPhase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA studyJ Clin Oncol201129326427121149659
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• YamamotoDIwaseSKitamuraKOdagiriHYamamotoCNagumoYA phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 TrialCancer Chemother Pharmacol200861350951417516068
   PubMed Web of Science ®Google Scholar
• MichalakiVFotiouSGennatasSGennatasCTrastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II resultsAnticancer Res20103073051305420683054
   PubMed Web of Science ®Google Scholar
• FountzilasGTsavdaridisDKalogera-FountzilaAWeekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II studyAnn Oncol200112111545155111822753
   PubMed Web of Science ®Google Scholar
• GaspariniGGionMMarianiLRandomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancerBreast Cancer Res Treat2007101335536516850247
   PubMed Web of Science ®Google Scholar
• RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerJ Clin Oncol200624182786279216782917
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar